← 홈

ADC · CD19

3개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3개
ADCBBiologicADC TherapeuticsthatPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 94.1%임상시험 48상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19B (SGN-CD19B)

Non-Hodgkin Lymphoma; DLBCL · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED